Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.

ABSTRACT: Late detection, compromised immune system, and chemotherapy resistance underlie the poor patient prognosis for pancreatic ductal adenocarcinoma (PDAC) patients, making it the 3^rd leading cause of cancer-related deaths in the United States. Cooperation between the tumor cells and the immune system leads to the immune escape and eventual establishment of the tumor. For more than 20 years, sincere efforts have been made to intercept the tumor-immune crosstalk and identify the probable therapeutic targets for breaking self-tolerance toward tumor antigens. However, the success of these studies depends on detailed examination and understanding of tumor-immune cell interactions, not only in the primary tumor but also at distant systemic niches. Innate and adaptive arms of the immune sy

SUBMITTER: Mundry CS 

PROVIDER: S-EPMC7483650 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature